14-day Premium Trial Subscription Sign Up For FreeGet Free

When Should You SELL Your Stocks? Click to watch.

Adaptimmune Therapeutics plc Stock Forecast

NASDAQ:ADAP BUY SELL

$1.64 (-1.80%)

Volume: 263.166k

Closed: May 20, 2022

Hollow Logo Score: -1.940

Adaptimmune Therapeutics plc Stock Forecast

BUY SELL NASDAQ:ADAP
$1.64 (-1.80%)

Volume: 263.166k

Closed: May 20, 2022

Score Hollow Logo -1.940

Adaptimmune Therapeutics plc Stock Price (Quote) NASDAQ:ADAP

$1.64 ( -1.80% ) Friday, 20th May 2022

Range Low Price High Price Comment
30 days $1.26 $2.32 Friday, 20th May 2022 ADAP stock ended at $1.64. This is 1.8% less than the trading day before Thursday, 19th May 2022. During the day the stock fluctuated 13.59% from a day low at $1.55 to a day high of $1.76.
90 days $1.26 $2.93
52 weeks $1.26 $6.86

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
2022-05-20 $1.73 $1.76 $1.55 $1.64 263 166
2022-05-19 $1.45 $1.79 $1.43 $1.67 785 467
2022-05-18 $1.56 $1.56 $1.46 $1.47 121 804
2022-05-17 $1.52 $1.61 $1.46 $1.57 377 187
2022-05-16 $1.40 $1.48 $1.37 $1.42 211 540
2022-05-13 $1.37 $1.46 $1.35 $1.41 272 511
2022-05-12 $1.33 $1.43 $1.26 $1.35 718 533
2022-05-11 $1.53 $1.54 $1.33 $1.33 623 387
2022-05-10 $1.56 $1.64 $1.48 $1.56 556 378
2022-05-09 $1.75 $1.97 $1.50 $1.54 830 713
2022-05-06 $1.75 $1.78 $1.65 $1.71 1 116 541
2022-05-05 $1.90 $1.91 $1.77 $1.78 192 517
2022-05-04 $1.85 $1.92 $1.76 $1.91 370 970
2022-05-03 $1.90 $1.91 $1.81 $1.82 223 358
2022-05-02 $1.70 $1.87 $1.70 $1.87 361 217
2022-04-29 $1.74 $1.83 $1.71 $1.72 297 815
2022-04-28 $1.75 $1.77 $1.65 $1.75 5 514 648
2022-04-27 $1.81 $1.84 $1.73 $1.75 395 201
2022-04-26 $1.92 $1.93 $1.80 $1.80 402 638
2022-04-25 $1.89 $1.97 $1.85 $1.96 258 426
2022-04-22 $1.92 $1.96 $1.85 $1.89 353 900
2022-04-21 $2.00 $2.06 $1.88 $1.91 766 400
2022-04-20 $1.97 $2.32 $1.93 $2.01 1 759 700
2022-04-19 $1.81 $1.96 $1.81 $1.92 299 200
2022-04-18 $1.92 $1.92 $1.83 $1.84 449 700
2022-04-14 $1.96 $1.97 $1.88 $1.91 575 126
2022-04-13 $1.77 $1.95 $1.77 $1.95 1 187 842
2022-04-12 $1.88 $1.90 $1.78 $1.79 541 136
2022-04-11 $2.13 $2.13 $1.84 $1.86 1 102 930
2022-04-08 $2.25 $2.34 $2.15 $2.18 545 200
2022-04-07 $2.25 $2.34 $2.22 $2.24 503 000
2022-04-06 $2.18 $2.30 $2.10 $2.28 690 200
2022-04-05 $2.20 $2.24 $2.17 $2.17 438 600
2022-04-04 $2.12 $2.26 $2.12 $2.23 506 100
2022-04-01 $2.07 $2.15 $2.01 $2.12 355 751
2022-03-31 $2.07 $2.07 $2.02 $2.06 279 824
2022-03-30 $2.14 $2.16 $2.03 $2.07 218 210
2022-03-29 $2.07 $2.18 $2.05 $2.13 316 400
2022-03-28 $2.08 $2.13 $2.01 $2.05 460 500
2022-03-25 $2.22 $2.22 $2.06 $2.10 455 600
2022-03-24 $2.17 $2.24 $2.12 $2.19 463 800
2022-03-23 $2.24 $2.26 $2.15 $2.16 510 900
2022-03-22 $2.13 $2.26 $2.08 $2.25 586 696
2022-03-21 $2.18 $2.19 $2.10 $2.13 1 012 195
2022-03-18 $2.06 $2.24 $2.04 $2.18 1 332 013
2022-03-17 $1.82 $2.11 $1.80 $2.11 1 844 200
2022-03-16 $1.76 $1.87 $1.76 $1.84 1 907 400
2022-03-15 $1.80 $1.85 $1.69 $1.73 1 327 500
2022-03-14 $1.83 $1.90 $1.77 $1.82 1 046 600
2022-03-11 $1.90 $1.93 $1.81 $1.82 1 135 100

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company’s lead program includes NY-ESO cancer antigen, which is in Phase 1/2 clinical trials for the... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!
.

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT